Updated:
Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. is an Israeli biopharmaceutical company focused on developing anti-inflammatory therapies, primarily through its proprietary...
Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. is an Israeli biopharmaceutical company focused on developing anti-inflammatory therapies, primarily through its proprietary anti-IL-17 antibody platform. The firm's lead candidate targets psoriasis and psoriatic arthritis, conditions with large, established treatment markets. Scinai's approach centers on modulating the interleukin-17 pathway, a validated mechanism in autoimmune disease management. The company's strategic posture combines internal drug development with a search for external partnerships or asset monetization. In April 2023, Scinai announced a restructuring plan to preserve cash and focus exclusively on its nanoantibody pipeline, discontinuing earlier COVID-19 therapy programs (per the firm's official communications, 2023). The firm lists its American Depositary Shares on the Nasdaq under the ticker SCNI, providing a public-market funding avenue uncommon for platform-stage biotechs of its size. Scinai maintains a lean operational footprint from its base in Jerusalem, Israel, leveraging the country's deep talent pool in immunology research. The firm's intellectual property estate centers on nanoantibodies — smaller, potentially more stable alternatives to conventional monoclonal antibodies. This technological differentiation informs its ongoing discussions with larger pharmaceutical partners. A key structural differentiator for Scinai is its status as a publicly listed pure-play biotech with no approved commercial products, making its equity function as a de facto funding vehicle for preclinical and early-clinical assets. This forces an unusual alignment between retail shareholders and drug-development timelines, distinct from the closed-end venture funds that typically back comparable science.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
What is Scinai Immunotherapeutics' lead therapeutic program?
Scinai's lead program targets the interleukin-17 (IL-17) pathway to treat plaque psoriasis and psoriatic arthritis. The firm's technology uses nanoantibodies, which are engineered antibody fragments derived from alpaca-derived VHH domains. These molecules are designed to offer improved tissue penetration and stability relative to conventional monoclonal antibodies.
How is Scinai Immunotherapeutics funded?
Scinai is a publicly traded company listed on the Nasdaq Capital Market under the ticker SCNI. This provides access to equity capital markets rather than being dependent solely on private venture rounds. The firm has also pursued non-dilutive funding through grants and collaborations tied to its infectious disease work, though its 2023 restructuring narrowed its focus to the immunology pipeline.
What happened to Scinai's COVID-19 therapy programs?
In April 2023, Scinai announced a restructuring that discontinued its COVID-19 therapeutic programs to preserve capital. The firm redirected resources entirely toward its anti-IL-17 nanoantibody platform for inflammatory diseases, citing a less crowded and more commercially viable path forward in immunology versus pandemic-related indications.
Who are Scinai Immunotherapeutics' likely partners or competitive peers?
Scinai operates in the IL-17 inhibitor landscape alongside established biologics from Novartis (Cosentyx), Eli Lilly (Taltz), and Johnson & Johnson (Tremfya). Unlike these large pharmaceutical companies, Scinai is a platform-stage developer seeking a partnership or licensing deal to advance its candidates through late-stage trials and commercialization.
What corporate structure does Scinai Immunotherapeutics use?
Scinai is structured as a conventional public Israeli limited company with American Depositary Shares trading on Nasdaq, rather than as a private venture-backed startup. This public listing subjects the firm to SEC reporting requirements and quarterly earnings disclosures, creating a transparency profile uncommon among preclinical biotechs.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: